The purpose of this study is to investigate in patients with cancer of the throat and
recurrent inoperable a different modality treatment consisting of radiation continuously for
5 weeks and half associated with a drug directed against a receptor on cell surfaces cancer,
called Erbitux ®.
The investigators hope with this shorter treatment (1.5 weeks less than the usual treatment)
to improve the antitumor efficacy without additional toxic side effects.